Prenatal screening US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Prenatal screening. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Prenatal screening US Medical PG Question 1: A 32-year-old G1P0 woman undergoes her 2nd-trimester ultrasound in a community hospital. During her prenatal care, she was found to have mild anemia, low levels of folate, and serum alpha-fetoprotein levels greater than 2 multiples of the median (MoM) on 2 separate occasions. Her 1st-trimester ultrasound was significant for the absence of the intracranial lucency, no visualization of the cisterna magna, and posterior shift of the brain stem. These 2nd-trimester ultrasound reports reveal the widening of the lumbosacral spine ossification centers and the presence of a sac in proximity to the lumbosacral defect. Which of the following statements best describes the congenital defect in the fetus?
- A. Abnormal development of the caudal eminence
- B. Persistence of the anterior accessory neurenteric canal (ANC)
- C. Failure of the caudal neuropore to close (Correct Answer)
- D. Failure of mesenchymal cells to form a neural rod
- E. Failure of the rostral neuropore to close
Prenatal screening Explanation: ***Failure of the caudal neuropore to close***
- The constellation of findings, including **elevated alpha-fetoprotein (AFP)**, absence of intracranial lucency, no visualization of the cisterna magna, posterior shift of the brain stem, widening lumbosacral spine ossification centers, and a sac near a lumbosacral defect, points to a **neural tube defect**, specifically an **open spina bifida** (myelomeningocele).
- This condition results from the **incomplete closure of the neural tube**, particularly the **caudal neuropore**, which normally closes around day 27-28 of embryonic development.
*Abnormal development of the caudal eminence*
- **Caudal eminence defects** typically manifest as caudal regression syndrome, which involves abnormalities of the sacrum and lower limbs, but usually **not** an open neural tube defect with elevated AFP and characteristic cranial ultrasound findings.
- While there is a lumbosacral defect, the extensive features point away from an isolated caudal eminence issue.
*Persistence of the anterior accessory neurenteric canal (ANC)*
- **Persistent ANC** is a rare condition that can lead to **duplications of the neural tube** or gastrointestinal tract, often associated with a connection between the gut and the neural canal.
- This would not explain the high AFP, absence of intracranial lucency, or the specific sonographic features of an open neural tube defect like spina bifida.
*Failure of mesenchymal cells to form a neural rod*
- The formation of the neural tube is a complex process; while mesenchymal cells are involved in surrounding structures, the neural rod itself primarily forms from the **neuroectoderm**.
- This description does not accurately reflect the embryological origin of spina bifida, which is fundamentally a defect of neural tube closure rather than a failure of neural rod formation.
*Failure of the rostral neuropore to close*
- Failure of the **rostral (cranial) neuropore** to close leads to **anencephaly** or encephalocele, characterized by the absence of a significant portion of the brain and skull.
- While AFP levels would be high, the ultrasound findings of a sac in the lumbosacral region and the specific intracranial findings (e.g., absence of intracranial lucency, posterior shift of the brain stem, which are signs of Arnold-Chiari malformation type II) are much more consistent with a caudal defect like myelomeningocele.
Prenatal screening US Medical PG Question 2: A 29-year-old primigravid woman at 18 weeks’ gestation comes to the physician for her first prenatal visit. She works as a paralegal and lives with her husband. Her current pregnancy was unexpected, and she did not take any prenatal medications or supplements. Physical examination shows a uterus 2 inches above the umbilicus. The concentration of α-fetoprotein in the maternal serum and concentrations of both α-fetoprotein and acetylcholinesterase in the amniotic fluid are elevated. Ultrasonography of the uterus shows an increased amniotic fluid volume. The fetus most likely has which of the following conditions?
- A. Anencephaly (Correct Answer)
- B. Holoprosencephaly
- C. Spina bifida occulta
- D. Myelomeningocele
- E. Lissencephaly
Prenatal screening Explanation: ***Anencephaly***
- **Elevated maternal serum α-fetoprotein (MSAFP)** and **amniotic fluid α-fetoprotein (AFAFP)**, along with elevated **acetylcholinesterase (AChE)** in amniotic fluid, are classic markers for **open neural tube defects**. Anencephaly, characterized by the **absence of a major portion of the brain and skull**, is an open neural tube defect.
- The **increased amniotic fluid volume (polyhydramnios)** is due to the fetus's inability to swallow amniotic fluid, a common finding in anencephaly.
*Holoprosencephaly*
- This condition involves incomplete separation of the **prosencephalon (forebrain)**, leading to **severe facial abnormalities** and brain malformations.
- While it is a severe brain malformation, it is typically a **closed neural tube defect** or a developmental anomaly not involving an open lesion, and therefore, it is usually not associated with elevated MSAFP, AFAFP, or AChE.
*Spina bifida occulta*
- This is the **mildest form of spina bifida**, involving a small gap in the vertebrae without protrusion of the spinal cord or meninges.
- It is a **closed neural tube defect** and is typically asymptomatic, often not associated with elevated MSAFP or AFAFP levels.
*Myelomeningocele*
- While a **myelomeningocele** is an **open neural tube defect** that would cause elevated MSAFP, AFAFP, and AChE, it is characterized by the protrusion of the spinal cord and meninges through a vertebral defect.
- The primary characteristic of anencephaly (absence of a major portion of the brain/skull) better fits the severe degree of neural tube defect suggested by the findings, particularly the polyhydramnios due to absent swallowing reflex.
*Lissencephaly*
- This is a brain malformation characterized by a **lack of gyri and sulci**, resulting in a smooth brain surface.
- It is a brain development defect, not an **open neural tube defect**, and as such, it is not associated with elevated MSAFP, AFAFP, or AChE.
Prenatal screening US Medical PG Question 3: A 37-year-old woman presents for prenatal counseling at 18 weeks gestation. The patient tells you that her sister recently had a child with Down's syndrome, and the patient would like prenatal screening for Down's in her current pregnancy.
Which of the following prenatal screening tests and results would raise concern for Down's syndrome?
- A. Increased AFP, normal HCG, normal unconjugated estriol
- B. Decreased AFP, decreased HCG, decreased unconjugated estriol
- C. Normal AFP, increased HCG, decreased unconjugated estriol
- D. Normal AFP, decreased HCG, decreased unconjugated estriol
- E. Decreased AFP, increased HCG, decreased unconjugated estriol (Correct Answer)
Prenatal screening Explanation: ***Decreased AFP, increased HCG, decreased unconjugated estriol***
- A classic finding in **Down's syndrome (trisomy 21)** during the second-trimester screen is a **decreased alpha-fetoprotein (AFP)**, **increased human chorionic gonadotropin (HCG)**, and **decreased unconjugated estriol**.
- This combination, sometimes referred to as the "**triple screen**" (or "quad screen" with inhibin A), indicates a higher risk of chromosomal abnormalities like trisomy 21.
*Increased AFP, normal HCG, normal unconjugated estriol*
- **Increased AFP** is typically associated with **neural tube defects** (e.g., spina bifida, anencephaly) or **ventral wall defects**, not Down's syndrome.
- Normal HCG and unconjugated estriol would argue against trisomy 21.
*Decreased AFP, decreased HCG, decreased unconjugated estriol*
- When all three markers (AFP, HCG, and unconjugated estriol) are **decreased**, it is highly suggestive of **trisomy 18 (Edwards syndrome)**, not Down's syndrome.
- Trisomy 18 is associated with severe developmental abnormalities and a poor prognosis.
*Normal AFP, increased HCG, decreased unconjugated estriol*
- While **increased HCG** and **decreased unconjugated estriol** are consistent with Down's syndrome, a **normal AFP** alone would make this less classic for trisomy 21 compared to the option with decreased AFP.
- The combination of **decreased AFP** alongside the other two findings is more characteristic.
*Normal AFP, decreased HCG, decreased unconjugated estriol*
- This pattern (normal AFP, decreased HCG, decreased unconjugated estriol) is not typically associated with Down's syndrome.
- **Decreased HCG** is more commonly seen in trisomy 18 in combination with decreased AFP and estriol.
Prenatal screening US Medical PG Question 4: A 36-year old pregnant woman (gravida 4, para 1) presents at week 11 of pregnancy. Currently, she has no complaints. She had an uncomplicated 1st pregnancy that ended in an uncomplicated vaginal delivery at the age of 28 years. Her male child was born healthy, with normal physical and psychological development over the years. Two of her previous pregnancies were spontaneously terminated in the 1st trimester. Her elder sister has a child born with Down syndrome. The patient denies smoking and alcohol consumption. Her blood analysis reveals the following findings:
Measured values
Beta human chorionic gonadotropin (beta-hCG) High
Pregnancy-associated plasma protein-A (PAPP-A) Low
Which of the following is the most appropriate next step in the management of this patient?
- A. Perform an ultrasound examination with nuchal translucency and crown-rump length measurement
- B. Recommend chorionic villus sampling with subsequent cell culturing and karyotyping (Correct Answer)
- C. Offer a blood test for rubella virus, cytomegalovirus, and toxoplasma IgG
- D. Recommend amniocentesis with subsequent cell culturing and karyotyping
- E. Schedule a quadruple test at the 15th week of pregnancy
Prenatal screening Explanation: ***Recommend chorionic villus sampling with subsequent cell culturing and karyotyping***
- The patient's **advanced maternal age** (36 years), history of **recurrent first-trimester miscarriages**, and a **family history of Down syndrome** in her sister's child are significant risk factors for **chromosomal abnormalities**.
- The abnormal first-trimester screening results (**high beta-hCG, low PAPP-A**) are highly suggestive of **aneuploidies**, particularly **Down syndrome (Trisomy 21)**. **Chorionic villus sampling (CVS)** is the most appropriate next step for definitive diagnosis as it can be performed earlier (10-13 weeks) than amniocentesis for definitive diagnosis via karyotyping.
*Perform an ultrasound examination with nuchal translucency and crown-rump length measurement*
- While a **nuchal translucency (NT) measurement** is part of the first-trimester screening and would confirm an increased risk, it is a screening, not a diagnostic, test.
- Given the patient's strong risk factors and abnormal biochemical markers, a definitive diagnostic test is warranted rather than another screening measure.
*Offer a blood test for rubella virus, cytomegalovirus, and toxoplasma IgG*
- This patient has a history of recurrent miscarriages and a family history suggestive of chromosomal abnormalities, along with abnormal first-trimester biochemical markers.
- While infections can cause miscarriage, the clinical picture strongly points towards a **chromosomal etiology**, making infection screening less urgent as a primary next step.
*Recommend amniocentesis with subsequent cell culturing and karyotyping*
- **Amniocentesis** is a diagnostic test for chromosomal abnormalities but is typically performed later in pregnancy, usually between **15 and 20 weeks**.
- Given the patient is at 11 weeks, **CVS** is the more appropriate and earlier diagnostic option for definitive diagnosis of potential aneuploidies.
*Schedule a quadruple test at the 15th week of pregnancy*
- The **quadruple test** is a second-trimester screening test and would provide more risk assessment rather than a definitive diagnosis.
- The patient already has strong indications for a chromosomal abnormality based on age, history, and first-trimester screening, necessitating an **earlier definitive diagnostic test**.
Prenatal screening US Medical PG Question 5: A 37-year-old primigravid woman comes to the physician at 13 weeks' gestation for a prenatal visit. She feels well. Her only medication is folic acid. Vital signs are within normal limits. Pelvic examination shows a uterus consistent in size with a 13-week gestation. Ultrasonography shows a nuchal translucency above the 99th percentile. Maternal serum pregnancy-associated plasma protein A is decreased and human chorionic gonadotropin concentrations are elevated to 2 times the median level. Which of the following is most likely to confirm the diagnosis?
- A. Chorionic villus sampling (Correct Answer)
- B. Cell-free DNA testing
- C. Triple screening test
- D. Amniocentesis
- E. Quadruple marker test
Prenatal screening Explanation: ***Chorionic villus sampling***
- This procedure can be performed between **10 to 13 weeks of gestation** to obtain fetal cells for genetic analysis, which is within the patient's gestational age.
- It provides a definitive diagnosis of **chromosomal abnormalities** by directly sampling placental tissue, which shares the same genetic material as the fetus.
*Cell-free DNA testing*
- While it has high sensitivity and specificity for various **aneuploidies**, it is a **screening test**, not a diagnostic one.
- An abnormal result from cell-free DNA testing still requires **confirmatory diagnostic testing** such as CVS or amniocentesis.
*Triple screening test*
- This test is typically performed between **15 and 20 weeks of gestation**, which is too late to confirm the findings presented at 13 weeks gestation.
- It measures **AFP, hCG, and unconjugated estriol**, and an abnormal result would indicate a need for further diagnostic testing.
*Amniocentesis*
- This procedure is generally performed later in pregnancy, typically between **15 and 20 weeks gestation**, so it would require waiting several more weeks.
- While it provides definitive genetic results, **chorionic villus sampling is preferred at 13 weeks** due to earlier diagnostic potential.
*Quadruple marker test*
- This test is also performed between **15 and 20 weeks of gestation** and measures **AFP, hCG, unconjugated estriol, and inhibin A**.
- It is a **screening test**, similar to the triple screen, and does not provide a definitive diagnosis, requiring further confirmatory testing if abnormal.
Prenatal screening US Medical PG Question 6: A 34-year-old gravida 2 para 1 woman at 16 weeks gestation presents for prenatal care. Her prenatal course has been uncomplicated. She takes no medications besides her prenatal vitamin which she takes every day, and she has been compliant with routine prenatal care. She has a 7-year-old daughter who is healthy. The results of her recent quadruple screen are listed below:
AFP: Low
hCG: Low
Estriol: Low
Inhibin-A: Normal
Which of the following is the most appropriate next step to confirm the diagnosis?
- A. Chorionic villus sampling
- B. Amniocentesis (Correct Answer)
- C. Ultrasound for nuchal translucency
- D. Folic acid supplementation
- E. Return to clinic in 4 weeks
Prenatal screening Explanation: ***Amniocentesis***
- The presented quad screen results (low AFP, low hCG, low estriol, normal Inhibin-A) are highly suggestive of **trisomy 18 (Edwards syndrome)**. Amniocentesis is a **definitive diagnostic test** that can confirm aneuploidy by providing a fetal karyotype.
- While typically performed between **15 and 20 weeks gestation**, it can differentiate between trisomy 18 and trisomy 21 (Down syndrome), which usually presents with high hCG and high Inhibin-A.
*Chorionic villus sampling (CVS)*
- **CVS** is typically performed earlier in pregnancy, between **10 and 13 weeks gestation**, meaning it is too late to perform at 16 weeks gestation.
- While it can provide a fetal karyotype for genetic diagnosis, the gestational age presented in the vignette makes this option currently inappropriate.
*Ultrasound for nuchal translucency*
- **Nuchal translucency (NT)** is part of the first-trimester screening, usually measured between **11 and 14 weeks gestation**.
- At 16 weeks gestation, measuring NT would be **outside the appropriate timeframe**, and the second-trimester quad screen has already been completed, making further screening rather than diagnosis less useful.
*Folic acid supplementation*
- **Folic acid supplementation** is crucial before and during early pregnancy to prevent neural tube defects, which would be associated with high AFP.
- The patient is already taking prenatal vitamins (which contain folic acid), and her quad screen results are not indicative of a neural tube defect but rather a chromosomal abnormality.
*Return to clinic in 4 weeks*
- The abnormal quad screen results indicate a **high risk for aneuploidy**, specifically trisomy 18, which requires immediate follow-up and definitive diagnosis.
- Delaying further assessment for 4 weeks would be clinically inappropriate and could increase patient anxiety and potentially reduce options for further management.
Prenatal screening US Medical PG Question 7: A 38-year-old woman, gravida 3, para 2, at 12 weeks' gestation comes to her obstetrician for a prenatal visit. Screening tests in the first trimester showed a decreased level of pregnancy-associated plasma protein and an increased level of β-hCG. A genetic disorder is suspected. Which of the following results from an additional diagnostic test is most likely to confirm the diagnosis?
- A. Decreased estriol in maternal serum
- B. Increased inhibin A in maternal serum
- C. Triploidy in amniotic fluid
- D. Increased nuchal translucency on ultrasound
- E. Trisomy 21 on chorionic villus sampling (Correct Answer)
Prenatal screening Explanation: ***Trisomy 21 on chorionic villus sampling***
- The combination of **decreased PAPP-A** and **increased β-hCG** in the first trimester is highly suggestive of **Trisomy 21 (Down syndrome)**.
- **Chorionic villus sampling (CVS)** is a diagnostic test performed in the first trimester that can directly analyze fetal chromosomes to confirm the presence of Trisomy 21.
*Decreased estriol in maternal serum*
- This finding is typically seen in the **second-trimester quad screen** (along with α-fetoprotein, β-hCG, and inhibin A), not the first-trimester screening.
- While low estriol is associated with aneuploidies, it's not the most direct or earliest confirmatory diagnostic test in this specific scenario.
*Increased inhibin A in maternal serum*
- Similar to estriol, **increased inhibin A** is a marker used in the **second-trimester quad screen** and is associated with Trisomy 21.
- It is not a component of the standard first-trimester screening blood tests mentioned (PAPP-A and β-hCG).
*Triploidy in amniotic fluid*
- **Triploidy** is a rare and severe chromosomal abnormality (three sets of chromosomes) with a distinct pattern on first-trimester screening (often very low β-hCG and PAPP-A, along with severe growth restriction and structural anomalies).
- The observed screening results (decreased PAPP-A, increased β-hCG) are much more characteristic of Trisomy 21 than triploidy.
*Increased nuchal translucency on ultrasound*
- **Increased nuchal translucency (NT)** is a significant **screening marker** for aneuploidies, including Trisomy 21, and is part of the first-trimester combined screening.
- While a strong indicator, it is a screening result, not a definitive diagnostic confirmation like chromosomal analysis from CVS.
Prenatal screening US Medical PG Question 8: A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?
- A. Perform 3-hour oral glucose tolerance test at 16 weeks
- B. Diagnose gestational diabetes based on random glucose and begin treatment
- C. Perform 1-hour glucose challenge test now
- D. Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes (Correct Answer)
- E. Defer screening until 24-28 weeks gestation per routine protocol
Prenatal screening Explanation: ***Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes***
- A **BMI ≥ 30 kg/m²** is a major risk factor necessitating early screening at the first prenatal visit to identify **pre-existing (overture) diabetes**.
- Identifying hyperglycemia early in pregnancy allows for immediate management to reduce the risk of **congenital anomalies** associated with pre-gestational diabetes.
*Perform 1-hour glucose challenge test now*
- While the **1-hour GCT** is a valid tool for early screening, standard biomarkers like **fasting plasma glucose** or **HbA1c** are also appropriate for detecting overt diabetes at the initial visit.
- The goal in the first trimester for high-risk patients is often to rule out **Type 2 Diabetes mellitus** that existed prior to pregnancy.
*Defer screening until 24-28 weeks gestation per routine protocol*
- Routine screening at **24-28 weeks** is reserved for women without significant risk factors; this patient's **obesity** mandates earlier evaluation.
- Delayed screening in obese patients may miss a window for intensive **glycemic control** during critical fetal organogenesis.
*Diagnose gestational diabetes based on random glucose and begin treatment*
- A **random glucose of 118 mg/dL** is within the normal range and is not diagnostic of either GDM (which requires >200 mg/dL with symptoms) or overt diabetes.
- Diagnosis requires structured testing such as an **HbA1c ≥ 6.5%**, fasting glucose ≥ 126 mg/dL, or a formal **oral glucose tolerance test (OGTT)**.
*Perform 3-hour oral glucose tolerance test at 16 weeks*
- The **3-hour OGTT** is typically the second step of a two-step screening process and is not indicated as an initial screening tool at 16 weeks.
- High-risk patients should be screened as soon as possible, often at the **first prenatal visit** (12 weeks in this case), rather than waiting until the second trimester.
Prenatal screening US Medical PG Question 9: A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?
- A. Annual fecal immunochemical testing
- B. Repeat colonoscopy in 3 years
- C. Repeat colonoscopy in 10 years
- D. Repeat colonoscopy in 1 year
- E. Repeat colonoscopy in 5-10 years (Correct Answer)
Prenatal screening Explanation: ***Repeat colonoscopy in 5-10 years***
- According to the **USMSTF 2020 guidelines**, patients with **1 to 2 small (<10 mm) tubular adenomas** should have a surveillance colonoscopy in **7-10 years**; however, for a single adenoma **≥ 10 mm** (like this 1.2 cm lesion) with low-grade dysplasia, the recommended interval is **5-10 years**.
- This recommendation balances the slightly higher risk of a **larger lesion** against the **low-grade pathology** and the patient's age and overall risk profile.
*Repeat colonoscopy in 10 years*
- A strictly **10-year interval** is reserved for patients with a **normal colonoscopy** or those with only **distal hyperplastic polyps**.
- While 10 years is the upper limit of the recommended range, the presence of a **1.2 cm adenoma** requires a surveillance designation rather than a standard screening interval.
*Repeat colonoscopy in 3 years*
- The **3-year interval** is indicated for **high-risk findings** such as **≥3 adenomas**, adenomas with **villous histology**, or those with **high-grade dysplasia**.
- This patient only had a single lesion with **low-grade dysplasia**, making 3-year surveillance an over-utilization of resources.
*Repeat colonoscopy in 1 year*
- A **1-year interval** is generally only indicated for cases of **incomplete resection**, piece-meal removal of large sessile polyps, or **inadequate bowel preparation**.
- It is not appropriate for a **completely removed** 1.2 cm tubular adenoma.
*Annual fecal immunochemical testing*
- **Fecal immunochemical testing (FIT)** is a primary **screening modality**, not a surveillance tool for patients who have already been diagnosed with adenomas via colonoscopy.
- Once an adenoma is identified, the patient enters a **colonoscopy-based surveillance** program to directly monitor for recurrent or advancing lesions.
Prenatal screening US Medical PG Question 10: A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?
- A. Begin mammography at age 35 and annually thereafter
- B. Recommend clinical breast exam every 6 months only
- C. Begin annual mammography now
- D. Refer for genetic counseling and consider expanded testing with breast MRI screening (Correct Answer)
- E. Reassure that negative BRCA testing indicates average risk
Prenatal screening Explanation: ***Refer for genetic counseling and consider expanded testing with breast MRI screening***
- Despite a negative **BRCA1/2** result, the patient's pedigree shows a **high-risk family history** (early-onset breast and ovarian cancer), which may indicate other **high-penetrance mutations** like **PALB2, TP53, or PTEN**.
- Women with a **lifetime risk >20%** based on models (e.g., **Tyrer-Cuzick**) or those with hereditary risk require **supplemental screening with Breast MRI** in addition to mammography.
*Begin annual mammography now*
- **Annual mammography alone** is insufficient for patients with a significant hereditary risk profile; **Breast MRI** is required to improve sensitivity in high-risk populations.
- Screening usually begins at age 30 or **10 years earlier** than the youngest diagnosis in the family, but current guidelines prioritize comprehensive **risk assessment** first.
*Reassure that negative BRCA testing indicates average risk*
- A negative test in the patient (without a known familial mutation) is **uninformative**; it does not rule out other genetic drivers or a strong **polygenic risk**.
- Reassuring her as "average risk" ignores the significant **familial clustering** of cancer, potentially delaying lifesaving early detection measures.
*Recommend clinical breast exam every 6 months only*
- **Clinical breast exams** lack the sensitivity to serve as a standalone management strategy for women with high **familial risk**.
- Evidence suggests that clinical exams do not significantly reduce **mortality** compared to advanced imaging protocols in hereditary cancer syndromes.
*Begin mammography at age 35 and annually thereafter*
- This delay is inappropriate; for high-risk families, screening often starts at **age 25 to 30** depending on the specific history and risk models.
- Starting at age 35 without incorporating **MRI screening** or updated **multi-gene panel testing** fails to address her specific hereditary risk profile.
More Prenatal screening US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
